Aldose Reductase Inhibitors and Other Potential Therapeutic Agents for the Treatment of Diabetic Neuropathy
TL;DRAbstract
It has been more than 20 yr since the first aldose reductase inhibitor was tested in diabetic and galactosemic rats and found to control polyol accumulation (1). Since then, a considerable number of aldose reductase inhibitors have been tested in experimental and human diabetes and have considerably increased our knowledge in this field (Table 1). A thorough review of work on experimental diabetes would be outside the scope of this volume; however, the interested reader can find more information in recently published extensive reviews. The following chapter will focus on the results from clinical trials in diabetic neuropathy (2,3).
Chat with Paper
AI Agents for this Paper
It has been more than 20 yr since the first aldose reductase inhibitor was tested in diabetic and galactosemic rats and found to control polyol accumulation (1). Since then, a considerable number of aldose reductase inhibitors have been tested in experimental and human diabetes and have considerably increased our knowledge in this field (Table 1). A thorough review of work on experimental diabetes would be outside the scope of this volume; however, the interested reader can find more information in recently published extensive reviews. The following chapter will focus on the results from clinical trials in diabetic neuropathy (2,3).
Keywords
Chat
Click to start Chat